JNJ•benzinga•
Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden
Summary
Nanobiotix amended its $2.7 billion licensing deal with Johnson & Johnson, reducing costs while retaining key milestone payments. The update extends its cash runway to mid-2026.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 18, 2025 by benzinga